Cost of Treatment and Care for People with Alzheimer’s Disease: A Meta- Analysis

Author(s): Petra Marešová*, Josef Dolejs, Hana Mohelska, Laura K. Bryan.

Journal Name: Current Alzheimer Research

Volume 16 , Issue 14 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

There is now a general attempt in developed countries to implement strategic plans to fight against Alzheimer’s disease, for which treatment represents an increasing economic burden for the ageing society. At present, the costs of treatment and care for Alzheimer’s Disease (AD) patients are not consistently tracked and logged, therefore, the economic burden is calculated based on the records kept by individual countries. The aim of this paper is to conduct a meta-analysis of the available data on the total costs of treatment and care for elderly AD patients with respect to the stage of the disease determined by the Mini Mental State Examination (MMSE). The Web of Science and PubMed databases were used for a systematic search. Two independent reviewers screened the identified records and selected relevant articles published in the period from 2007 to 2017. A meta-analysis of costs is performed in three categories related to the stages of Alzheimer’s disease (mild, moderate, and severe). The resulting estimation of total costs per patient per year determined by the meta-analysis is 20,461$ total costs. The total costs in relation to the stage of the disease according to the MMSE scale are 14,675 $ for the mild stage, 19,975 $ for the moderate stage, and 29,708 $ for the severe stage. The meta- analysis confirms that the costs rise significantly with the severity of AD. These findings therefore, emphasize the severity of the economic burden carried out by the AD patients, their families, and the healthcare system, and this fact must be taken into account when planning health policy strategies for the years to come.

Keywords: Alzheimer's disease, meta-analysis, costs, mini mental state examination, developed countries, mental disorders.

[1]
World Health Organization Mental Health Available from: [cited 2018 March 19].. http://www.euro.who.int/en/health-topics/noncommunicable-diseases/mental-health/mental-health
[2]
Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 17(2): 189-202. (2017)
[http://dx.doi.org/10.1080/14737167.2017.1313118] [PMID: 28351177]
[3]
Amjad H, Wong SK, Roth DL, Huang J, Willink A, Black BS, et al. Health services utilization in older adults with dementia receiving care coordination: the MIND at home trial. Health Serv Res 53(1): 556-79. (2018)
[http://dx.doi.org/10.1111/1475-6773.12647] [PMID: 28083879]
[4]
Michalowsky B, Flessa S, Eichler T, Hertel J, Dreier A, Zwingmann I, et al. Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial. Eur J Health Econ 19(1): 87-102. (2018)
[http://dx.doi.org/10.1007/s10198-017-0869-7] [PMID: 28160100]
[5]
Daras LC, Feng Z, Wiener JM, Kaganova Y. Medicare expenditures associated with hospital and emergency department use among beneficiaries with dementia. Inquiry 54 46958017696757 (2017)
[http://dx.doi.org/10.1177/0046958017696757] [PMID: 28301976]
[6]
Holmerová I, Hort J, Rusina R, Wimo A, Šteffl M. Costs of dementia in the Czech Republic. Eur J Health Econ 18(8): 979-86. (2017)
[http://dx.doi.org/10.1007/s10198-016-0842-x] [PMID: 27785577]
[7]
Butler A, Gallagher D, Gillespie P, Crosby L, Ryan D, Lacey L, et al. Frailty: a costly phenomenon in caring for elders with cognitive impairment. Int J Geriatr Psychiatry 31(2): 161-8. (2016)
[http://dx.doi.org/10.1002/gps.4306] [PMID: 26136186]
[8]
Schaller S, Mauskopf J, Kriza C, Wahlster P, Kolominsky-Rabas PL. The main cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry 30(2): 111-29. (2015)
[http://dx.doi.org/10.1002/gps.4198] [PMID: 25320002]
[10]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7) e1000097 (2009)
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[11]
Wells G, Shea B, O’Connell J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis (2001) http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAvailable from.: URL. http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp
[12]
Olazarán J, Agüera-Ortiz L, Argimón JM, Reed C, Ciudad A, Andrade P, et al. Costs and quality of life in community-dwelling patients with Alzheimer’s disease in Spain: results from the GERAS II observational study. Int Psychogeriatr 29(12): 2081-93. (2017)
[http://dx.doi.org/10.1017/S1041610217001211] [PMID: 28720158]
[13]
Michalowsky B, Thyriana JR, Eichler T, Hertel J, Wucherer D, Flessa S, et al. Economic analysis of formal care, informal care, and productivity losses in primary care patients who screened positive for dementia in Germany. J Alzheimers Dis 50: 47-59. (2016)
[14]
Wimo A, Reed CC. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer’s disease in three european countries - study design and baseline findings. J Alzheimers Dis 36 (2013) 385-99. (2013)
[15]
Dodel A, Belger M, Reed C, Wimo A, Jones RW, Happich M, et al. Determinants of societal costs in Alzheimer’s disease: GERAS study baseline results. Alzheimers Dement 11(8): 933-45. (2015)
[16]
Gustavssona A, Brinckc P, Bergvall N, Kolasa K, Wimo A, Winblad B, et al. Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement 7: 318-27. (2011)
[http://dx.doi.org/10.1016/j.jalz.2010.09.001]
[17]
Rattingera GR, Schwartz S, Mullins CD, Corcoran C, Zuckerman IH, Sanders C, et al. Dementia severity and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement 11: 946-54. (2015)
[http://dx.doi.org/10.1016/j.jalz.2014.11.004]
[18]
Wang G, Chenga Q. Economic impact of dementia in developing countries: an evaluation of alzheimer-type dementia in shanghai, China. J Alzheimer Dise 15: 109-15. (2008)
[19]
Gillespie P, O’Shea E, Cullinan J, Lacey L, Gallagher D, Ni Mhaolain A. The effects of dependence and function on costs of care for Alzheimer’s disease and mild cognitive impairment in Ireland. Int J Geriatr Psychiatry 28(3): 256-64. (2013)
[http://dx.doi.org/10.1002/gps.3819] [PMID: 23386588]
[20]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414): 557-60. (2003)
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[21]
Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2): 193-206. (2006)
[http://dx.doi.org/10.1037/1082-989X.11.2.193] [PMID: 16784338]
[22]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 21(11): 1539-58. (2002)
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[23]
Borenstein M, Hedges L, Rothstein H. Meta-Analysis Fixed effect vs random effects [cited 2018 March 19] Available from. https://www.meta-analysis.com/downloads/M-a_f_e_v_r_e_sv.pdf
[24]
Fang JQ. Medical statistics and computer experiments. New Jersey: World Scientific 2005; p. 948.
[http://dx.doi.org/10.1142/5762]
[25]
Gillespie P, O’Shea E, Cullinan J, Buchanan J, Bobula J, Lacey L, et al. Longitudinal costs of caring for people with Alzheimer’s disease. Int Psychogeriatr 27(5): 847-56. (2015)
[http://dx.doi.org/10.1017/S1041610214002063] [PMID: 25248030]
[26]
Colucci L, Bosco M, Fasanaro AM, Gaeta GL, Ricci G, Amenta F. Alzheimer’s disease costs: what we know and what we should take into account. J Alzheimers Dis 42(4): 1311-24. (2014)
[http://dx.doi.org/10.3233/JAD-131556] [PMID: 25024334]
[27]
Tsolaki M, Papaliagkas V, Frisoni G, Jones R, Touchon J, Spiru L, et al. MCI Patients in Europe: medication and comorbidities. The DESCRIPA Study. Curr Alzheimer Res 13(12): 1407-13. (2016)
[http://dx.doi.org/10.2174/1567205013666160603002704] [PMID: 27335041]
[28]
Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease-a simulation study. Curr Alzheimer Res 10(2): 207-16. (2013)
[http://dx.doi.org/10.2174/1567205011310020011] [PMID: 23036018]
[29]
Yang KC, Chen HH. Probabilistic cost-effectiveness analysis of vaccination for mild or moderate Alzheimer’s disease. Curr Alzheimer Res 13(7): 809-16. (2016)
[http://dx.doi.org/10.2174/1567205013666160129095012] [PMID: 26825097]
[30]
van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med 62(4): 835-45. (2006)
[http://dx.doi.org/10.1016/j.socscimed.2005.06.046] [PMID: 16137814]
[31]
Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 5(1): 13-23. (1996)
[http://dx.doi.org/10.1002/(SICI)1099-1050(199601)5:1<13:AID-HEC182>3.0.CO;2-J] [PMID: 8653189]
[32]
Rattinger GB, Schwartz S, Mullins CD, Corcoran C, Zuckerman IH, Sanders C, et al. Dementia severity and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement 11(8): 946-54. (2015)
[http://dx.doi.org/10.1016/j.jalz.2014.11.004] [PMID: 25614127]
[33]
Kiencke P, Daniel D, Grimm C, Rychlik R. Direct costs of Alzheimer’s disease in Germany. Eur J Health Econ 12(6): 533-9. (2011) Epub 2010 Jul 18
[http://dx.doi.org/10.1007/s10198-010-0267-x]
[34]
Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den Bussche H, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand 124(5): 384-95. (2011)
[http://dx.doi.org/10.1111/j.1600-0447.2011.01741.x] [PMID: 21838738]
[35]
Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L. Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res 7(4): 358-67. (2010)
[http://dx.doi.org/10.2174/156720510791162430] [PMID: 19939223]
[36]
Mohelska H, Maresova P, Valis M, Kuca K. Alzheimer's disease and its treatment costs: case study in the Czech Republic. Neuropsychiatric Disease and Treatment 11 (2015) 2349-54. (2015)
[37]
Maresova P, Mohelska H, Kuca K. A Social and family load of Alzheimer’s disease. App Eco 48(21): 1936-48. (2016)
[38]
Maresova P, Klimova B, Novotny M, Kuca K. Alzheimer’s and Parkinson’s disease: expected economic impact on Europe - a call for a uniform European strategy. J Alzheimers Dis 54(3): 1123-33. (2016)
[http://dx.doi.org/10.3233/JAD-160484] [PMID: 27567862]
[39]
Wimo A, Jönsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement 9(1): 1-11.e3. (2013)
[http://dx.doi.org/10.1016/j.jalz.2012.11.006] [PMID: 23305821]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 14
Year: 2019
Page: [1245 - 1253]
Pages: 9
DOI: 10.2174/1567205017666200102144640
Price: $65

Article Metrics

PDF: 31
HTML: 5
EPUB: 2